Muntelukast + Placebo
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Respiratory Tract Infection
Conditions
Upper Respiratory Tract Infection
Trial Timeline
Nov 1, 2007 → Jun 1, 2010
NCT ID
NCT00551382About Muntelukast + Placebo
Muntelukast + Placebo is a phase 3 stage product being developed by Merck for Upper Respiratory Tract Infection. The current trial status is unknown. This product is registered under clinical trial identifier NCT00551382. Target conditions include Upper Respiratory Tract Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00551382 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Upper Respiratory Tract Infection